Levitra® Therapy Suitable For Men With High Cholesterol
1) The double-blind, placebo-controlled proof in approximately 400 men showed that Levitra® significantly improved the power of men with erectile dysfunction (ED) and altitudinous cholesterol, to actualize and look after an erection for crowned sexual intercourse.( 2) The trial, led by Dr.
Martin Miner, clinical associate professor of family medicine at Brown University, Swansea, Massachusetts, was the headmost prospective glance at designed to evaluate Levitra's safety and efficacy in patients with dyslipidemia (high cholesterol) and ED.
All test participants were bewitching statins to government their dyslipidemia. The results of the 12-week probation showed that men randomized to obtain Levitra® had significantly increased ascendancy rates of penetration and the potency to keep an erection compared to placebo. Erectile dysfunction is actual oftentimes associated with high rise cholesterol.
Copious physicians are not treating ED, a life-changing condition", said Mister Ian Eardley, consultant urologist and honorary senior orator at St. James University Hospital, Leeds.
This announce provides as well foothold that Levitra® can successfully treat ED, still in men with a downbeat underlying action conforming eminent cholesterol. The accumulating evidence shows that Levitra® is a potent treatment for ED in men with underlying conditions", he emphasized at the EAU congress in Milan. ED and testosterone deficiency recurrently help the identical underlying conditions such as dyslipidemia, cardiovascular disease and obesity.
The presence of ED should automatically trigger tests to form testosterone levels, as testosterone deficiency is a expressive detriment to endowment of life. Very presented at the EAU in Milan, original material from the European Testogel®-Study, which showed that testosterone therapy with Testogel® may edit cardiovascular and metabolic conditions and character of vitality in men with low testosterone (hypogonadism).(
3) In the international, multicenter, randomized, double-blind, placebo-controlled study, 362 men aged 50-80 with dilatory on-set hypogandism (LOH), i.e. Testogel® or placebo for 6 months, followed by a 12-month open-label sheet during which all patients received Testogel.
Over the beginning six months, Testogel® avail was associated with eloquent improvements in cardiovascular and metabolic profiles, as great as quality-of-life scores as measured by the aging man symptom scale (AMS) compared to placebo.
